Physician profile
Prashanth Mannam
NPI 1104090935
$4,781.79
in general payments reported to CMS, 2019-2025
28 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $1,106 · 2021: $1,150 · 2022: $254 · 2023: $566 · 2024: $44.62 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $654.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $585.48 | 2019-2022 | |
| Novo Nordisk INC | $573.38 | 2019-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $503.29 | 2023 | Onyx Frontier, Symplicity G3 |
| Lilly USA, LLC | $415.15 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.35 | 2019-2022 | |
| Pfizer INC. | $273.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $267.70 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $224.71 | 2019-2021 | |
| Amarin Pharma, INC. | $125.52 | 2019-2020 | |
| Abbott Laboratories | $112.47 | 2021-2022 | |
| Abbvie INC. | $110.11 | 2019 | |
| Amgen INC. | $92.38 | 2019-2021 | |
| Shield Therapeutics INC | $89.50 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $82.73 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $64.42 | 2025 | Inspire |
| Exact Sciences Corporation | $62.55 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $49.52 | 2019-2022 | |
| Horizon Therapeutics Plc | $47.18 | 2019-2021 | |
| Bausch Health US, LLC | $24.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.77 | 2020 | |
| Redhill Biopharma INC. | $18.61 | 2020 | |
| Circassia INC. | $16.52 | 2020 | |
| Tandem Diabetes Care, INC. | $15.89 | 2019 | |
| Esperion Therapeutics, INC. | $14.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.60 | 2021 | |
| Gilead Sciences, INC. | $13.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashanth Mannam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.